No Detail Found!

Comparison of Postprandial Insulin Levels in Withania coagulans and Liraglutide Treated Diabetic Rats.

Author(s)
Abdul Samad Department of Physiology Pak International Medical College, Peshawar, Pakistan
Shazia Ali Department of Physiology Islamic International Medical College, Riphah International University, Islamabad, Pakistan
Noman Sadiq Department of Physiology CMH Kharian Medical College, Kharian, Pakistan
Abstract
Objective: To investigate and compare the antidiabetic effect of withania coagulans and Liraglutide on serum postprandial insulin levels in streptozotocin induced diabetes in rats. Study Design: Randomized Control Trial. Place and Duration of Study: The study was conducted from 1st April 2016 to 31st March 2017 at Islamic International Medical College in collaboration with National Institute of Health Islamabad. Materials and Methods: Total 40 male Sprague dawley rats were randomly divided into two groups; Group A (n=10) and Experimental Group (n=30). Group A was given normal diet for 5 days whereas experimental group was given normal diet plus streptozotocin (30mg/kg/day) intraperitoneally for 5 days and diabetes was confirmed in experimental group by fasting blood glucose (mg/dl). Experimental group was further divided into B (Diabetic control), C (Withania coagulans treated) and D (Liraglutide treated). First sampling group A and B was done after 5 days. Group C were given Withania coagulans and Group D were given Liraglutide along with normal diet for 30 days. Second sampling (fasting blood glucose, postprandial glucose and insulin level) was done from group C and D. Results: Fasting blood glucose of group C (98 mg/dl ± 1.80) was significantly reduced than group D (102 mg/dl ± 2.04). Postprandial glucose and insulin levels of Group D (163 mg/dl ± 3.95 and 6.06 µU/ml ±0.17) were significantly decreased and increased as compared to Group C PPG (183 mg/dl ± 6.30) and insulin level (5.54 µU/ml ± 0.23). Conclusion: Withania Coagulans significantly improves postprandial insulin levels as compared to liraglutide.
Publication Details
Page(s) 206-209
DOI DOI not available
Published Journal: Journal of Islamic International Medical College, Volume: 13, Issue: 4, Year: 2018

Request the full text from PASTIC

References
TiernaLM,MepheeSJ,PapadakisMA, 2002.Diabetes mellitus and hypoglycemia. Current medical diagnosis and treatment,41st ed. New York: McGraw Hill 1203 -44
WildS,RoglicG,GreenA,SicreeR,KingH, 2004.Diabetes care, 27 1047 -53
Russell-JonesD,VaagA,SchmitzO,SethiBK,LalicN,AnticS, 2009.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial,Diabetologia 52 2046 -55
MorrisDH,KhuntiK,AchanaF,SrinivasanB,GrayLJ,DaviesMJ, 2013.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis Diabetologia,Progression rates from HbA1c 6 56 1489 -93
WhiteWB,PratleyR,FleckP,MunsakaM,HisadaM,WilsonC, 2013.Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus,Diabetes, Obesity and Metabolism 15 668 -73
Kaneto H. Pancreatic, 2016.-cell failure in type 2 diabetes mellitus,Expert Review of Endocrinology & Metabolism 11 1 -2
Ismail-Beigi F, 2012.Glycemic management of type 2 diabetes mellitus,New England Journal of Medicine 366 1319 -27
DeFronzoRA, 2000.Pharmacologic therapy for type 2 diabetes mellitus,Annals of internal medicine 133 73 -
Kolterman , O.G, 2003.Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with T2DM,J. Clin. Endocrinol. Metab 132 3082 -3089
Nielsen , L.L.,Young , A.A.,Parkes , D.G., 2004.Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improves glycemic control of T2DM, 117 77 -88
Pabreja , K., 2014."Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation,British journal of pharmacology 171 1114 -1128
2006.Chansouria; Hypolipidemic activity of aqueous extract of Withania coagulans Dunal in albino rats,Phytotherapy Research 20 614 -617
JaiswalD,RaiPK,WatalG, 2009.Antidiabetic effect of Withania coagulans in experimental rats,Indian Journal of Clinical Biochemistry 24 88 -93
ShuklaK, 2014.Hypolipidemic and antioxidant activity of aqueous extract of fruit of Withania coagulans (Stocks) Dunal in cholesterol-fed hyperlipidemic rabbit model,Indian Journal of Experimental biology 56 870 -875
BhartiSK, 2012.Antidiabetic effect of aqueous extract of Withania coagulans flower inPoloxamer-407 induced type 2 diabetic rats,Journal of Medicinal Plants Research 6 5706 -13
ShuklaK,DikshitP,ShuklaR,GambhirJK, 2012.The aqueous extract of Withania coagulans fruit partially reverses nicotinamide/streptozotocin-induced diabetes mellitus in rats,Journal of medicinal food 15 718 -25
Datta, 2013.A etal. Antidiabetic and antihyperlipidemic activity of hydroalcoholic extracts of Withania coagulans Dunal dried fruit in experimental rat models,Journal of Ayurveda and integrative medicine 4 99 -04
AlamA,SiddiquiMY,HakimMH., 2009.Clinical efficacy of Withania coagulans Dunal and Trigonella foenum-graecum Linn. in Type 2 Diabetes mellitus,Indian journal of traditional Knowledge 8 405 -409
DaviesMJ, 2015.Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial,Jama 314 687 -99
UpadhyayBN,GuptaV., 2011.A clinical study on the effect of Rishyagandha (Withania coagulans) in the management of Prameha (Type II Diabetes Mellitus),AYU (An international quarterly Journal of research in Ayurveda) 32 507 -12
0

Citations

0

Downloads

57

Views